Clinical Trial Update: Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase II study of Abraxane (paclitaxel albumin-bound) plus ipilimumab in metastatic melanoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• ipilimumab (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-08